<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00725777</url>
  </required_header>
  <id_info>
    <org_study_id>IDC-08-01</org_study_id>
    <nct_id>NCT00725777</nct_id>
  </id_info>
  <brief_title>Treatment of Non-falciparum Malaria</brief_title>
  <official_title>Efficacy and Safety of Artemether Lumefantrine Combination Therapy for the Treatment of Malaria Due to Plasmodium Ovale, Plasmodium Malariae, and Mixed Plasmodium Infections in Gabon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Schweitzer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Albert Schweitzer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with non-falciparum infection will be given artemether-lumefantrine for three days
      and will be followed up for 28 days. Besides efficacy and safety evaluations a substudy on
      immunology will be performed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parasitological cure rate on day 28</measure>
    <time_frame>D28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of drug related adverse events</measure>
    <time_frame>D28</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Acute Non-falciparum Malaria</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>artemether-lumefantrine</intervention_name>
    <description>Standard artemether-lumefantrine treatment</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients between the age of 6 months and 60 years and with a minimum of
             5kg bodyweight

          -  Presence of uncomplicated malaria confirmed by: i)fever or history of fever in the
             previous 4 days, and ii)positive microscopy of P. malariae or P. ovale or mixed
             infection with P.falciparum with parasite density &gt; 50-200000/μl of blood

          -  Written informed consent

        Exclusion Criteria:

          -  Patients with presence of other clinical conditions requiring hospitalization

          -  Presence of other febrile conditions

          -  Presence of significant anemia, defined by hemoglobin &lt; 7g/dl

          -  Known history of hypersensitivity,allergic or adverse reactions to artemether or
             lumefantrine

          -  Intake of any antimalarial or antibiotics with known antimalarial activity in the
             preceding 2 weeks

          -  Pregnant and breast feeding females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabine Bélard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Research Unit of the Albert Schweitzer Hospital in Lambaréné</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Research Unit of the Albert Schweitzer Hospital</name>
      <address>
        <city>Lambaréné</city>
        <state>Moyen Ogooue</state>
        <zip>BP 118</zip>
        <country>Gabon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Gabon</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2008</study_first_submitted>
  <study_first_submitted_qc>July 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2008</study_first_posted>
  <last_update_submitted>February 16, 2012</last_update_submitted>
  <last_update_submitted_qc>February 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Schweitzer Hospital</investigator_affiliation>
    <investigator_full_name>Michael Ramharter</investigator_full_name>
    <investigator_title>Ass. Prof. PD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

